UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine cancers, aggressive tumors that can arise in the lung, prostate, and ovary, grow rapidly, spread early, and remain extremely difficult to treat. A defining feature of these cancers is the loss of a protective gene called RB, which normally acts as a brake on cell growth. Without RB, cancer cells multiply rapidly and resist many targeted therapies.
This article was originally published on MedicalXpress.com
